Holen Sie sich die Stockscreener-App
4.54
5.61%
-0.27
Handel nachbörslich:
4.72
0.18
+3.96%
Schlusskurs vom Vortag:
$4.81
Offen:
$4.83
24-Stunden-Volumen:
733.35K
Relative Volume:
0.58
Marktkapitalisierung:
$124.47M
Einnahmen:
$160.43M
Nettoeinkommen (Verlust:
$-227.64M
KGV:
-0.066
EPS:
-68.77
Netto-Cashflow:
$-170.79M
1W Leistung:
-4.62%
1M Leistung:
-35.69%
6M Leistung:
+29.71%
1J Leistung:
-3.61%
1-Tages-Spanne:
$4.4497
$4.84
1-Wochen-Bereich:
$4.06
$4.88
52-Wochen-Spanne:
$1.38
$7.34
Agenus Inc Stock (AGEN) Company Profile
Firmenname
Agenus Inc
Sektor
Branche
Telefon
781-674-4410
Adresse
3 FORBES ROAD, LEXINGTON, MA
Vergleichen Sie AGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
4.54 | 131.88M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-02-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-28 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-04-22 | Eingeleitet | B. Riley FBR | Buy |
| 2016-10-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Bestätigt | Maxim Group | Buy |
| 2016-03-11 | Hochstufung | Maxim Group | Hold → Buy |
| 2015-12-16 | Eingeleitet | Jefferies | Buy |
| 2015-10-27 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-07-27 | Bestätigt | MLV & Co | Buy |
| 2015-06-11 | Eingeleitet | Oppenheimer | Outperform |
| 2015-01-12 | Bestätigt | Maxim Group | Buy |
| 2015-01-09 | Bestätigt | MLV & Co | Buy |
| 2015-01-09 | Bestätigt | Maxim Group | Buy |
| 2014-12-19 | Bestätigt | Maxim Group | Buy |
| 2014-05-08 | Bestätigt | Maxim Group | Buy |
| 2014-03-14 | Bestätigt | MLV & Co | Buy |
| 2013-10-08 | Bestätigt | Maxim Group | Buy |
| 2012-01-05 | Eingeleitet | William Blair | Outperform |
| 2011-12-01 | Eingeleitet | Global Hunter Securities | Buy |
Alle ansehen
Agenus Inc Aktie (AGEN) Neueste Nachrichten
U.S. Pharmaceutical CDMO Market Valuation to Surpass USD 68.57 Billion by 2034 - GlobeNewswire Inc.
Agenus Inc Reports Q2 2025 Earnings: EPS Loss of $2.03, Revenue at $25.7 Million, Missing Estimates - GuruFocus
Agenus Faces Ongoing Risks Despite Stable Consensus - AInvest
Agenus Inc. Faces Ongoing Risks: What Investors Need to Know - TipRanks
Trapped Investors in Agenus Inc. Await Breakout SignalWatchlist for Low Risk High Return Stocks Updated - 선데이타임즈
Can Agenus Inc. disrupt its industryMultiplier Stock Alert - thegnnews.com
Agenus Inc. shares rise 2.29% after-hours following Q2 earnings report. - AInvest
Agenus: Cash Starved Pharma Counting On Bot/Bal Cancer Bounty (NASDAQ:AGEN) - Seeking Alpha
Agenus 2025 Q2 Earnings Improved Losses Amid Strategic Momentum - AInvest
Agenus Inc. shares fall 3.75% premarket after reporting a $30 million loss in Q2 earnings. - AInvest
Agenus stock price target lowered to $23 by H.C. Wainwright on higher expenses - Investing.com Nigeria
Agenus Inc. Reports Q2 2025 Financial Results - TipRanks
Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates - sharewise.com
Agenus: Q2 Earnings Snapshot - San Francisco Chronicle
Agenus Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Agenus Posts 48% Q2 Revenue Miss - AOL.com
Agenus Reports Q2 2025 Financials, Secures $91M, and Plans Phase 3 Trial for BOT/BAL Therapy. - AInvest
Agenus: A Contrarian Play on Immuno-Oncology's Next Frontier Amid Financial Reengineering - AInvest
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress - Stock Titan
Is Agenus Inc. exposed to currency risksHigh Profit Stock Recommendations - kangso.co.kr
Agenus Earnings Outlook: Analysts Expect $0.50 EPS in Q2 2025 - AInvest
Agenus AGEN Q2 2025 Earnings Preview Upside Potential on Strategic CDMO Shift - AInvest
Examining the Future: Agenus's Earnings Outlook - 富途牛牛
Should value investors consider Agenus Inc.ROI Enhanced Trading Plan - newsyoung.net
Smart tools for monitoring Agenus Inc.’s price actionLong Term Stock Growth Plan Suggestions - Newser
Why Agenus Inc. stock attracts strong analyst attentionInsider Strategy for High Conviction Picks - Newser
Tools to monitor Agenus Inc. recovery probabilityLong-Term Stock Growth Forecast Insights - Newser
Agenus Inc. shares fall 2.41% intraday after Delhi High Court restrains Zydus Lifesciences from launching nivolumab biosimilar. - AInvest
How many analysts rate Agenus Inc. as a “Buy”Build a portfolio that outperforms the market - Jammu Links News
What institutional investors are buying Agenus Inc. stockMaximize portfolio value with expert tips - Jammu Links News
Agenus Inc. Stock Analysis and ForecastMaximize returns with strategic portfolio planning - Jammu Links News
Is Agenus Inc. a growth stock or a value stockAchieve superior returns through strategic trading - Jammu Links News
What markets is RILYL expanding into Is Agenus Inc. stock a good long term investment optionConsistently high yield - Jammu Links News
Why is Agenus Inc. stock attracting strong analyst attentionExceptional trading results - Jammu Links News
What makes Agenus Inc. stock price move sharplyCapitalize on proven investment strategies - Jammu Links News
Should I hold or sell Agenus Inc. stock in 2025Discover stocks with explosive potential - Jammu Links News
What analysts say about Agenus Inc. stockMaximize returns with strategic trading plans - Jammu Links News
How strong is Agenus Inc. company’s balance sheetAchieve rapid portfolio growth with expert guidance - Jammu Links News
Is Agenus Inc. a good long term investmentRapid wealth creation - Jammu Links News
What is the dividend policy of Agenus Inc. stockHigh-velocity capital appreciation - Jammu Links News
What are the latest earnings results for Agenus Inc.Consistently profitable trades - Jammu Links News
What are analysts’ price targets for Agenus Inc. in the next 12 monthsMarket-beating returns - Jammu Links News
Statistical indicators supporting Agenus Inc.’s strengthRetirement Investment Outlook and Return Summary - Newser
Agenus Announces Q2 2025 Financial Results, Stakeholder Briefing to Highlight Botensilimab and Balstilimab Programs - AInvest
Is Agenus Inc. stock overvalued or undervaluedEarnings Report Alerts To Watch Now - Jammu Links News
Zacks.com featured highlights include QuantumScape, Civeo and Agenus - The Globe and Mail
QuantumScape, Civeo, and Agenus Lead the Way in Earnings Acceleration - AInvest
Finanzdaten der Agenus Inc-Aktie (AGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):